GlaxoSmithKline plc

The U.S. Food and Drug Administration on Friday said it would review GlaxoSmithKline's experimental treatment for multiple myeloma, a common form of blood cancer, for a reported side-effect which affects the eyes of patients.

* GSK AND MEDICAGO ANNOUNCE COLLABORATION TO DEVELOP A NOVEL ADJUVANTED COVID-19 CANDIDATE VACCINE

Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported.

Britain is close to agreeing a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of their potential COVID-19 vaccine, the Sunday Times reported.

The U.S. Food and Drug Administration on Thursday approved GlaxoSmithKline Plc's HIV drug, Rukobia, to treat adult patients who have run out of treatment options.

GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of research said on Thursday.

* GLAXOSMITHKLINE PLC - GSK’S DAPRODUSTAT GAINS FIRST REGULATORY APPROVAL

There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline.

There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline <GSK.L>.

* GSK COVID-19 VACCINE DEVELOPMENT COLLABORATION WITH CLOVER BIOPHARMACEUTICALS BEGINS CLINICAL TRIALS

* GSK - GSK PRICES $280.3 MILLION SENIOR NOTES DUE 2023 EXCHANGEABLE INTO THERAVANCE BIOPHARMA ORDINARY SHARES Source text for Eikon: Further company coverage:

* ANNOUNCES PROPOSED UNREGISTERED OFFERING OF SENIOR NOTES EXCHANGEABLE INTO THERAVANCE BIOPHARMA ORDINARY SHARES

* GSK - IDEAYA AND GSK ANNOUNCE A BROAD PARTNERSHIP IN SYNTHETIC LETHALITY, AN EMERGING FIELD IN PRECISION MEDICINE ONCOLOGY

* GLAXO SMITHKLINE CONSUMER NIGERIA PLC - QTRLY GROUP PROFIT BEFORE TAX 166.9 MILLION NAIRA VERSUS 150.6 MILLION NAIRA

GSK <GSK.L>, the world's largest vaccine maker, laid out plans on Thursday to produce 1 billion doses of vaccine efficacy boosters for COVID-19 shots next year, as the race to develop a successful solution to the coronavirus crisis heats up.

British drugmaker GlaxoSmithKline Plc will expand production of vaccine efficacy boosters, or adjuvants, to produce 1 billion doses in 2021 for use in shots for COVID-19, the company said on Thursday.

* GSK - ANNOUNCES INTENTION TO PRODUCE 1 BILLION DOSES OF PANDEMIC VACCINE ADJUVANT IN 2021 TO SUPPORT MULTIPLE COVID-19 VACCINE COLLABORATIONS

* GSK - FDA GRANTS PRIORITY REVIEW OF NUCALA FOR PATIENTS WITH HYPEREOSINOPHILIC SYNDROME (HES)

South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years.